Conn syndrome was named after J. W. Conn who first decribed it in 1955, in a patient who had hypertension with an aldosterone-producing adenoma. The ademona is characterized by increased aldosterone secretion from the adrenal glands, suppressed plasma renin, hypertension, and hypokalemia. Later, many other cases of adrenal hyperplasia with inappropriately elevated aldosterone secretion were described, and now the term primary hyperaldosteronism is used to describe Conn syndrome irrespective of whether the patient has an adenoma or not.
The syndrome may be secondary to adrenal hyperplasia, adrenal adenoma, aldosterone-secreting adrenal carcinoma (1%), or familial hyperaldosteronism (FH).
Various specific genetic alterations (see below) have been identified for rare familial forms of the disease. In a majority of these genetic alterations, the end point is Ca influx and membrane depolarization resulting in aldosterone hypersecretion.
Familial hyperaldosteronism (FH) type 1: Unequal crossing over between highly homologous CYP11B2 and CYP11B1 genes that code of aldosterone synthase and steroid 11 B-hydroxylase, resulting in a chimeric gene that is under adrenocorticotrophin (ACTH) rather than RAS control.
Familial hyperaldosteronism (FH) type 2: Autosomal dominant, heterogeneous, no response to dexamethasone suppression, possibly link with chromosome 7p22.
Familial hyperaldosteronism (FH) type 3: Mutations in the gene encoding the inwardly rectifying potassium channel Kir3.4 (KCNJ5 gene). Specific mutations in KCNJ5 gene, like those altering the G151E amino acid, are associated with a milder form of aldosteronism, compared to those with a G151R mutation that have a more severe form.
Mutations in three other genes encoding for membrane proteins (Na/K-ATPase (ATP1A), ca ATPase (ATP2B3) and Ca1.3 (CACNAID) are associated with Ca influx and/or activated calcium signaling pathways leading to increased production of aldosterone by CYP11B2 gene.
Recently, a single-nucleotide polymorphism (c.-2G>C) of the NR3C2 gene that codes for mineralocorticoid receptor (MR) has been shown to be associated with increased activation of RAS and increased blood pressure in the general population.
Primary hyperaldosteronism is the most common cause of secondary hypertension and occurs in about 6% to 20% of adult hypertensive patients, higher in patients with resistant hypertension. The prevalence of 10% was noted when consecutive patients with hypertension were evaluated. However, the prevalence increased to 30% when aldosterone to renin ratio (ARR) was used as a screening method in general practice.
Aldosterone-producing adenoma is present in 50% to 60%, and the remaining is idiopathic or bilateral adrenal hyperplasia. It is about two times more common in women than men.
Primary hyperaldosteronism is caused by aldosterone-producing adenomas, bilateral idiopathic adrenal hyperplasia, aldosterone-producing adrenal carcinoma, and familial aldosteronism. The increased amount of aldosterone potentiates renal sodium reabsorption and water retention, and potassium excretion. The increased sodium reabsorption by the kidneys results in plasma volume expansion which is the primary initiating mechanism for hypertension. This may induce tissue inflammation and heightened sympathetic drive, with subsequent development of fibrosis in vital organs, such as heart, kidneys, and vasculature. As a result, this may lead to the development of chronic kidney disease, atrial fibrillation, stroke, ischemic heart disease and congestive heart failure.
Histopathology is often heterogeneous ranging from micronodular or macronodular hyperplasia with adenoma formation, with atrophy or diffuse or nodular hyperplasia of the adjacent adrenal cortex.
Often, the patients are asymptomatic but may present with symptoms of fatigue, muscle weakness, cramping (secondary to potassium wasting), headaches, and palpitations. They can also have polydipsia and polyuria from hypokalemia-induced nephrogenic diabetes insipidus.
Hypokalemia in a hypertensive patient is the most common clue for primary hyperaldosteronism. However, normal serum potassium may be present in up to 38% of patients, especially in patients with adrenal hyperplasia or familial aldosteronism.
When to screen?
Unilateral adrenalectomy in patients with a unilateral adenoma (Conn syndrome) cures hypertension in 30 % to 60% of cases, but the mean cure rate is only 19% after unilateral or bilateral adrenalectomy in patients with idiopathic hyperaldosteronism whose treatment mainly is medical. This treatment includes aldosterone antagonists such as spironolactone or eplerenone or other potassium-sparing diuretics like amiloride.
Normal serum potassium level does not exclude primary hyperaldosteronism. Several studies have shown that 7% to 38% of patients with primary hyperaldosteronism have normal baselineserum potassium levels, especially patients with hypertension who are often advised to restrict their salt intake. The hypokalemia becomes evident with the liberalization of dietary sodium intake.
The ARR may be falsely elevated in patients with chronic kidney disease, patients on potassium supplements or beta-blockers. Diuretics, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers may cause false negative results. If the clinical suspicion is high, ARR should be repeated after holding these agents for two weeks.
|Adrenal Venous Sampling in Patients With Positive Screening but Negative Confirmatory Testing for Primary Aldosteronism., Umakoshi H,Naruse M,Wada N,Ichijo T,Kamemura K,Matsuda Y,Fujii Y,Kai T,Fukuoka T,Sakamoto R,Ogo A,Suzuki T,Nanba K,Tsuiki M,, Hypertension, 2016 May [PubMed PMID: 26975712]|
|Hyperaldosteronism: Screening and Diagnostic Tests., Sabbadin C,Fallo F,, High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2016 Mar 14 [PubMed PMID: 26971505]|
|Sodium interference in the determination of urinary aldosterone., Aldea ML,Barallat J,Martín MA,Rosas I,Pastor MC,Granada ML,, Clinical biochemistry, 2016 Feb [PubMed PMID: 26562029]|
|Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients., Lubitz CC,Economopoulos KP,Sy S,Johanson C,Kunzel HE,Reincke M,Gazelle GS,Weinstein MC,Gaziano TA,, Circulation. Cardiovascular quality and outcomes, 2015 Nov [PubMed PMID: 26555126]|
|Resistant hypertension with adrenal nodule: are we removing the right gland?, Das G,Taylor PN,Tabasum A,Rao Bondugulapati LN,Parker D,Baglioni P,Okosieme OE,Scott Coombes D,, Endocrinology, diabetes & metabolism case reports, 2015 [PubMed PMID: 26527194]|
|An Update on Familial Hyperaldosteronism., Korah HE,Scholl UI,, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2015 Dec [PubMed PMID: 26445452]|